157 related articles for article (PubMed ID: 38650367)
21. Comparison of visual and automated assessment of tumour inflammatory infiltrates in patients with colorectal cancer.
Forrest R; Guthrie GJ; Orange C; Horgan PG; McMillan DC; Roxburgh CS
Eur J Cancer; 2014 Feb; 50(3):544-52. PubMed ID: 24332571
[TBL] [Abstract][Full Text] [Related]
22. Differential clinical impacts of tumour budding evaluated by the use of immunohistochemical and haematoxylin and eosin staining in stage II colorectal cancer.
Yamadera M; Shinto E; Kajiwara Y; Mochizuki S; Okamoto K; Shimazaki H; Hase K; Ueno H
Histopathology; 2019 Jun; 74(7):1005-1013. PubMed ID: 30698857
[TBL] [Abstract][Full Text] [Related]
23. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer.
Dienstmann R; Villacampa G; Sveen A; Mason MJ; Niedzwiecki D; Nesbakken A; Moreno V; Warren RS; Lothe RA; Guinney J
Ann Oncol; 2019 Oct; 30(10):1622-1629. PubMed ID: 31504112
[TBL] [Abstract][Full Text] [Related]
24. The relationship between tumour budding, the tumour microenvironment and survival in patients with invasive ductal breast cancer.
Gujam FJ; McMillan DC; Mohammed ZM; Edwards J; Going JJ
Br J Cancer; 2015 Sep; 113(7):1066-74. PubMed ID: 26263482
[TBL] [Abstract][Full Text] [Related]
25. Preoperative, biopsy-based assessment of the tumour microenvironment in patients with primary operable colorectal cancer.
Park JH; van Wyk H; McMillan DC; Edwards J; Orange C; Horgan PG; Roxburgh CS
J Pathol Clin Res; 2020 Jan; 6(1):30-39. PubMed ID: 31486287
[TBL] [Abstract][Full Text] [Related]
26. Tumour budding predicts increased recurrence after curative resection for T2N0 colorectal cancer.
Garfinkle R; Lee L; Boutros M; Cardin MJ; Spatz A; Morin N
Can J Surg; 2019 Oct; 62(5):334-339. PubMed ID: 31550095
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive assessment of tumour budding by cytokeratin staining in colorectal cancer.
Rieger G; Koelzer VH; Dawson HE; Berger MD; Hädrich M; Inderbitzin D; Lugli A; Zlobec I
Histopathology; 2017 Jun; 70(7):1044-1051. PubMed ID: 28061021
[TBL] [Abstract][Full Text] [Related]
28. Tumour budding/T cell infiltrates in colorectal cancer: proposal of a novel combined score.
Dawson H; Christe L; Eichmann M; Reinhard S; Zlobec I; Blank A; Lugli A
Histopathology; 2020 Mar; 76(4):572-580. PubMed ID: 31560788
[TBL] [Abstract][Full Text] [Related]
29. Tumor microenvironmental factors have prognostic significances in advanced gastric cancer.
Ahn B; Chae YS; Kim CH; Lee Y; Lee JH; Kim JY
APMIS; 2018 Oct; 126(10):814-821. PubMed ID: 30264431
[TBL] [Abstract][Full Text] [Related]
30. JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors.
Pennel KAF; Hatthakarnkul P; Wood CS; Lian GY; Al-Badran SSF; Quinn JA; Legrini A; Inthagard J; Alexander PG; van Wyk H; Kurniawan A; Hashmi U; Gillespie MA; Mills M; Ammar A; Hay J; Andersen D; Nixon C; Rebus S; Chang DK; Kelly C; Harkin A; Graham J; Church D; Tomlinson I; Saunders M; Iveson T; Lannagan TRM; Jackstadt R; Maka N; Horgan PG; Roxburgh CSD; Sansom OJ; McMillan DC; Steele CW; Jamieson NB; Park JH; Roseweir AK; Edwards J
J Exp Clin Cancer Res; 2024 Mar; 43(1):64. PubMed ID: 38424636
[TBL] [Abstract][Full Text] [Related]
31. CXCL8 expression is associated with advanced stage, right sidedness, and distinct histological features of colorectal cancer.
Pennel KA; Quinn JA; Nixon C; Inthagard J; van Wyk HC; Chang D; Rebus S; ; Hay J; Maka NN; Roxburgh CS; Horgan PG; McMillan DC; Park JH; Roseweir AK; Steele CW; Edwards J
J Pathol Clin Res; 2022 Nov; 8(6):509-520. PubMed ID: 35879507
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic value of inflammatory cell infiltrates, tumor stroma percentage and disease-free survival in patients with colorectal cancer.
Jakubowska K; Kisielewski W; Kańczuga-Koda L; Koda M; Famulski W
Oncol Lett; 2017 Sep; 14(3):3869-3877. PubMed ID: 28927159
[TBL] [Abstract][Full Text] [Related]
33. Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer.
Al-Badran SS; Grant L; Campo MV; Inthagard J; Pennel K; Quinn J; Konanahalli P; Hayman L; Horgan PG; McMillan DC; Roxburgh CS; Roseweir A; Park JH; Edwards J
J Pathol Clin Res; 2021 Mar; 7(2):121-134. PubMed ID: 33338327
[TBL] [Abstract][Full Text] [Related]
34. Tumor Budding Correlates With the Protumor Immune Microenvironment and Is an Independent Prognostic Factor for Recurrence of Stage I Lung Adenocarcinoma.
Kadota K; Yeh YC; Villena-Vargas J; Cherkassky L; Drill EN; Sima CS; Jones DR; Travis WD; Adusumilli PS
Chest; 2015 Sep; 148(3):711-721. PubMed ID: 25836013
[TBL] [Abstract][Full Text] [Related]
35. Cancer-associated stroma reveals prognostic biomarkers and novel insights into the tumour microenvironment of colorectal cancer and colorectal liver metastases.
Brown KM; Xue A; Smith RC; Samra JS; Gill AJ; Hugh TJ
Cancer Med; 2022 Jan; 11(2):492-506. PubMed ID: 34874125
[TBL] [Abstract][Full Text] [Related]
36. High expression of STAT3 within the tumour-associated stroma predicts poor outcome in breast cancer patients.
Morrow E; Pennel K; Hatthakarnkul P; Leslie H; Mallon E; Andersen D; Jamieson N; McMillan D; Roseweir A; Edwards J
Cancer Med; 2023 Jun; 12(12):13225-13240. PubMed ID: 37199043
[TBL] [Abstract][Full Text] [Related]
37. Tumour budding at invasive margins and outcome in colorectal cancer.
Kanazawa H; Mitomi H; Nishiyama Y; Kishimoto I; Fukui N; Nakamura T; Watanabe M
Colorectal Dis; 2008 Jan; 10(1):41-7. PubMed ID: 18078460
[TBL] [Abstract][Full Text] [Related]
38. Budding and tumor-infiltrating lymphocytes - combination of both parameters predicts survival in colorectal cancer and leads to new prognostic subgroups.
Lang-Schwarz C; Melcher B; Haumaier F; Lang-Schwarz K; Rupprecht T; Vieth M; Sterlacci W
Hum Pathol; 2018 Sep; 79():160-167. PubMed ID: 29787819
[TBL] [Abstract][Full Text] [Related]
39. Intratumoral stromal morphometry predicts disease recurrence but not response to 5-fluorouracil-results from the QUASAR trial of colorectal cancer.
Hutchins GGA; Treanor D; Wright A; Handley K; Magill L; Tinkler-Hundal E; Southward K; Seymour M; Kerr D; Gray R; Quirke P;
Histopathology; 2018 Feb; 72(3):391-404. PubMed ID: 28746977
[TBL] [Abstract][Full Text] [Related]
40. The clinical utility of the local inflammatory response in colorectal cancer.
Richards CH; Roxburgh CS; Powell AG; Foulis AK; Horgan PG; McMillan DC
Eur J Cancer; 2014 Jan; 50(2):309-19. PubMed ID: 24103145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
